Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study-Reference-Cited by-同舟云学术

Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study

Published:2024-04-17 Issue:8 Volume:65 Page:1127-1135
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Aldoss Ibrahim¹,Zhang Jianying²,Robbins Marjorie¹,Song Joo³,Al Malki Monzr M.¹,Otoukesh Salman¹,Sandhu Karamjeet¹,Agrawal Vaibhav¹,Herrera Alex F.⁴,Popplewell Leslie L.⁴,Ghoda Lucy¹,Stein Anthony¹,Marcucci Guido¹,Forman Stephen¹,Pullarkat Vinod¹

Affiliation:

1. Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, California, USA

2. Division of Biostatistics, City of Hope National Medical Center, Duarte, California, USA

3. Department of Pathology, City of Hope National Medical Center, Duarte, California, USA

4. Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical center, Duarte, California, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2343029

Reference33 articles.

1. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

2. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial

3. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

4. Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab

5. Sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia